In conclusion, our study supports the involvement of glucagon signalling in metabolic disorders such as type 2 diabetes and MASLD and that increased proglucagon levels may predispose to type 2 diabetes. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.